Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUAL IV: Insulin Degludec/Liraglutide in T2D Inadequately Controlled on Sulphonylurea
NCT01618162Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2012
- Primary completion
- Oct 2013
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 3 trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Aug 2012; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01618162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01618162.